instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: Depression is one of the most common forms of mental illness, affecting more than 350 million people worldwide. It is ranked by the World Health Organization as the leading cause of disability globally. Treatment usually involves either medication, some form of psychotherapy or a combination of both. Yet many patients fail to get better and suffer recurring bouts of illness. MBCT was developed to help such people by teaching them skills to recognize and respond constructively to thoughts and feelings associated with relapse, aiming to prevent a downward spiral into depression. In the first large study to compare MBCT and anti-depressants, researchers found little difference in outcomes. In terms of cost, mindfulness training often viewed as more costly because it requires more time with a trained therapist was not significantly more pricey, particularly when given in group sessions, the study found. Richard Byng, a professor at Britain's Plymouth University Peninsula Schools of Medicine and Dentistry, said that, while current standard treatment for chronic depression is to keep taking anti-depressants, many people don't want to take them for long periods and others want to avoid side-effects. In this study, 424 adults with recurrent major depression who were on maintenance anti-depressant drugs were randomly assigned either to come off their anti-depressants slowly and receive MBCT or to stay on their medication. While 212 patients continued taking their anti-depressants, the other 212 attended eight group mindfulness therapy sessions and were given daily home practice as well as an option to have four follow-up sessions over a 12-month period. Study results published in The Lancet medical journal showed that after two years, relapse rates were similar in both groups at 44 percent in the therapy group versus 47 percent in the anti-depressant drug group. "Whilst this study doesn't show that mindfulness-based cognitive therapy works any better than maintenance anti-depressant medication in reducing the rate of relapse ... these results suggest a new choice for the millions of people with recurrent depression on repeat prescriptions," said Willem Kuyken of Oxford University, who worked with Byng on the research. Claim: Mindfulness therapy as good as medication for chronic depression - study.
answer:
Mindfulness-based cognitive therapy (MBCT) may be just as effective as anti-depressants in helping prevent people with chronic depression from relapsing, scientists said on Tuesday.

question:
Paragraph: After more than three hours of debate, lawmakers in parliament's upper house voted on Tuesday for a change in the law to allow the treatments, echoing a positive vote in the lower house earlier this month. The treatment, called mitochondrial transfer, is known as "three-parent" in vitro fertilization (IVF) because the babies, born from genetically modified embryos, would have DNA from a mother, a father and from a female donor. Although the techniques are still at the research stage in laboratories in Britain and the United States, experts say that now legal hurdles have been overcome, Britain's first 3-parent baby could be born as early as 2016. Mitochondrial transfer involves intervening in the fertilization process to remove faulty mitochondrial DNA, which can cause inherited conditions such as heart problems, liver failure, brain disorders, blindness and muscular dystrophy. Mitochondria act as tiny energy-generating batteries inside cells, and around 1 in 6,000 babies around the world are born with serious mitochondrial disorders. Responding to the vote, Jeremy Farrar, director of the Wellcome Trust medical charity commended lawmakers for a "considered and compassionate decision". "Families who know what it is like to care for a child with a devastating disease are the people best placed to decide whether mitochondrial donation is the right option," he said. Mark Downs, chief executive of the Society of Biology, hailed "a great day for UK science" and said the landmark decision "will ensure mothers who carry faulty mitochondria can have healthy children free from the devastating conditions." But Marcy Darnovsky, director of the campaign group The Center for Genetics and Society, called the move a "historic mistake" which turns children into biological experiments and will "forever alter the human germline". "The techniques ... are relatively crude and will not in and of themselves create so-called designer babies," she said. "However, they will result in children with DNA from three different people in every cell of their bodies, which will impact a large range of traits in unknowable ways and introduce genetic changes that will be passed down to future generations." Claim: Britain becomes first nation to legalize three-parent babies.
answer:
- Britain will become the first nation to legalize a "three-parent" IVF technique which doctors say can prevent some inherited incurable diseases but which critics fear will effectively lead to "designer babies".

question:
Paragraph: Teva Pharmaceutical Industries Ltd's rival migraine headache preventer is excluded on one list and patients can pay more for it in some cases on a second list, the note said. As with rival PBMs Express Scripts and CVS Health Corp, OptumRx's lists of covered drugs, or formularies, cover tens of millions of consumers who receive their healthcare from employers and health insurers. About 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, and global migraine drug sales could reach $8.7 billion by 2026, according to analytics firm GlobalData. OptumRx's decision secures easier access to customers for Lilly's Emgality at all three of the biggest PBMs - including CVS and Express Scripts - and gives Amgen's Aimovig a leg up after CVS decided not to include it on its preferred drug list. Teva's Ajovy only has preferred status at CVS, while Amgen also has it at Express Scripts, part of Cigna Corp. "We are pleased that all three companies have chosen Emgality to be one of the preferred medications, making it accessible to even more patients suffering from migraine," Lilly said in an emailed statement. Inclusion on a preferred drugs list by the largest PBMs and health insurers is critically important for sales of new medicines. Increasingly, PBMs are choosing a subset of treatments for their coverage list when there are multiple treatments that are considered equivalent. The three treatments, approved by the U.S. Food and Drug Administration last year, belong to a class of drugs called CGRP inhibitors that have proven effective in helping to prevent migraines. A Teva spokeswoman said the company is committed to increasing access to Ajovy regardless of formulary decisions and is still offering discounts that allow patients to pay nothing in some cases, regardless of insurance. "Since Ajovy injection launched in September, we have experienced strong demand and steady growth, and we continue discussions with payers," the spokeswoman said. An Amgen spokeswoman said that the company was pleased with the decision and is committed to ensuring affordable access to its drug. Amgen, which shares Aimovig U.S. revenue with Novartis AG, earlier this week reported fourth-quarter sales of $95 million, nearly doubling Wall Street estimates. The OptumRx decision becomes effective Feb. 1. The OptumRx select formulary relegates Teva's drug to a lower access level that would typically require a higher out-of-pocket cost, it said. PBMs typically extract discounts from drugmakers in return for favorable placement on their preferred list of covered drugs, such as through a low co-payment, or coinsurance payment, for their members. All three migraine drugs have a list price of $575 a month, or $6,900 a year. Those prices do not reflect the rebates and discounts to PBMs, who design and negotiate benefits for employers and insurers. All three drugmakers are providing a limited duration supply of the new drugs at no cost directly to patients in addition to other assistance programs. Amgen's Aimovig was first-to-market from the new class. But the rivals from Teva and Lilly followed soon after. The three large PBMs together cover the majority of the more than 150 million Americans who receive benefits through their employers. Their clients, including insurers and corporations, may choose not to follow a PBM's recommendations on coverage, but that typically would cost more. Amgen shares were off 28 cents at $186.63, Lilly was up nearly 1 percent at $120.90 and Teva shares traded in New York were down nearly 1 percent at $19.69. Claim: Exclusive: Top U.S. insurer to cover Amgen, Eli Lilly migraine drugs, exclude Teva.
answer:
A top U.S. pharmacy benefit manager (PBM) owned by UnitedHealth Group Inc has included new migraine drugs from Amgen Inc and Eli Lilly and Co as preferred treatments on its lists of covered drugs, according to an OptumRx client note viewed by Reuters.